News
Ocugen and Bharat Biotech to co-develop COVAXIN™, a whole-virion inactivated COVID-19 vaccine, for the US market
Companies will co-develop inactivated vaccine candidate, COVAXIN™, to prevent COVID-19 infection in the US. Builds upon the promising safety and immunogenicity data in the Phase 1 and Phase 2 trials. Vaccine candidate is an inactivated (“traditional”) type vaccine with potentially broad appeal
Karnataka aims to become $50 billion bioeconomy by 2025 - The Indian Express
The government released its first draft of the bio-economy report 2020 at the Bengaluru Tech Summit. While the report estimates the bio-economy of the state at USD 22.6 billion (Rs 1,67,240 crores) and growing at present, it is projected to USD 42 billion by 2025.
.jpg)
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
The strategic alliance between SII and the ICMR will advance India’s role in the global race to develop COVID-19 vaccines. ICMR is providing continuous support to SII in conducting and funding the ongoing clinical trials of COVISHIELD across 15 centres in India
Azooka, Bon Ayu, Nirmai Health win National Startup Awards 2020
Three well-known life sciences startups, Azooka Life Sciences, Nirmai Health Analytx and Bon Ayu are among the winners of National Startups Awards 2020 announced by the Government of India in 16 technology sectors. The awards were announced on October 6,2020.
Archives
The Crucibles of Enterprise 2021
